Business
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results
European revenues increased 20% compared to same period last yearGross margin of 39% compared to 35% in same period last yearNet loss improved 19% compared to
About this update from Sonoma Pharmaceuticals, Inc.
[{"type":"text","content":"European revenues increased 20% compared to same period last yearGross margin of 39% compared to 35% in same period last yearNet loss improved 19% compared to same period last year BOULDER, CO / ACCESSWIRE / August 8, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2024.\"This year marks the twentieth anniversary of the introduction of Sonoma wound care products into Europe; it is remarkable how our business has expanded and diversified in that time,\" remarked Amy Trombly, CEO of Sonoma. \"We're off to a strong start in fiscal year 2025, with first quarter results showing increased revenues in Europe and improved overall margins as compared to the prior year. We continue to expand our business and identify new markets for our products, while containing our costs, and we look forward to continued growth as a result of these achievements.\"Business HighlightsSonoma continued to meet customer needs by expanding our product offerings, entering new partnerships, and working with existing partners to expand our markets:On July 9, 2024, we announced an expansion of our distributor base in Europe through a new partnership with Smart Healthcare Company (SHC) s.r.o. for the distribution of Microdacyn60® wound care products into Ukraine.On May 9, 2024, we announced expansion of our MicrocynAH® animal health care products in the Menards® chain of home improvement stores in the United States, through our partner, Compana Pet Brands.On April 9, 2024, we announced expansion of our Microcyn® Negative Pressure Wound Therapy Solution products line, now available in 250mL, 450mL and 990mL sizes to meet the diverse needs of healthcare professionals and patients.Results for the Quarter Ended June 30, 2024Total revenues for the quarter ended June 30, 2024 of $3.4 million were flat as compared to $3.4 million for the same period last year. Revenues in Europe increased 20% compared to the same period last year as the result of increased demand for Sonoma's products. Revenues decrease...